Compare BBY & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBY | ILMN |
|---|---|---|
| Founded | 1966 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 18.9B |
| IPO Year | N/A | 2000 |
| Metric | BBY | ILMN |
|---|---|---|
| Price | $74.19 | $128.90 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 19 | 15 |
| Target Price | $84.24 | ★ $114.93 |
| AVG Volume (30 Days) | ★ 4.1M | 1.5M |
| Earning Date | 11-25-2025 | 10-30-2025 |
| Dividend Yield | ★ 5.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 3.02 | ★ 4.46 |
| Revenue | ★ $41,825,000,000.00 | $4,288,000,000.00 |
| Revenue This Year | $1.77 | N/A |
| Revenue Next Year | $1.32 | $2.08 |
| P/E Ratio | ★ $24.54 | $28.91 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $54.99 | $68.70 |
| 52 Week High | $91.68 | $153.06 |
| Indicator | BBY | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 66.70 |
| Support Level | $74.24 | $124.27 |
| Resistance Level | $83.67 | $129.72 |
| Average True Range (ATR) | 2.59 | 3.90 |
| MACD | -0.30 | -0.41 |
| Stochastic Oscillator | 11.07 | 77.82 |
With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.